San Francisco-based Harpoon Therapeutics has raised about $76m in an initial public offering, amid a biotech boom that shows no sign of slowing. Harpoon develops immunotherapies that direct the T cells of a patient to target and kill cancer cells. The company offered 5.4 million shares at $14 per share, with trading launching on Nasdaq on Friday 8 February. Shares rose more than 10% to close the day up nearly 13%. Its lead treatment, HPN424, is currently in a phase one trial for patients with advanced prostate cancer.
San Francisco-based Harpoon Therapeutics has raised about $76m in an initial public offering, amid a biotech boom that shows no sign of slowing. The company offered 5.4 million shares at $14 per share, with trading launching on Nasdaq on Friday 8 February. Shares rose more than 10% to close the day up nearly 13%. Its lead treatment, HPN424, is currently in a phase one trial for patients with advanced prostate cancer.